Autologous circulating angiogenic cells treated with osteopontin and delivered via a collagen scaffold enhance wound healing in the alloxan-induced diabetic rabbit ear ulcer model.
BACKGROUND
Diabetic foot ulceration is the leading cause of amputation in people with diabetes mellitus. Peripheral vascular disease is present in the majority of patients with diabetic foot ulcers. Despite standard treatments there exists a high amputation rate. Circulating angiogenic cells previously known as early endothelial progenitor cells are derived from peripheral blood and support angiogenesis and vasculogenesis, providing a potential topical treatment for non-healing diabetic foot ulcers.


METHODS
A scaffold fabricated from Type 1 collagen facilitates topical cell delivery to a diabetic wound. Osteopontin is a matricellular protein involved in wound healing and increases the angiogenic potential of circulating angiogenic cells. A collagen scaffold seeded with circulating angiogenic cells was developed. Subsequently the effect of autologous circulating angiogenic cells that were seeded in a collagen scaffold and topically delivered to a hyperglycemic cutaneous wound was assessed. The alloxan-induced diabetic rabbit ear ulcer model was used to determine healing in response to the following treatments: collagen seeded with autologous circulating angiogenic cells exposed to osteopontin, collagen seeded with autologous circulating angiogenic cells, collagen alone and untreated wound. Stereology was used to assess angiogenesis in wounds.


RESULTS
The cells exposed to osteopontin and seeded on collagen increased percentage wound closure as compared to other groups. Increased angiogenesis was observed with the treatment of collagen and collagen seeded with circulating angiogenic cells.


CONCLUSIONS
These results demonstrate that topical treatment of full thickness cutaneous ulcers with autologous circulating angiogenic cells increases wound healing. Cells exposed to the matricellular protein osteopontin result in superior wound healing. The wound healing benefit is associated with a more efficient vascular network. This topical therapy provides a potential novel therapy for the treatment of non-healing diabetic foot ulcers in humans.
Aonghus
A
O'Loughlin
Mangesh
M
Kulkarni
Erin E
EE
Vaughan
Michael
M
Creane
Aaron
A
Liew
Peter
P
Dockery
Abhay
A
Pandit
Timothy
T
O'Brien
D000496:Alloxan / Q000633:toxicity; D000818:Animals; D002478:Cells, Cultured; D024042:Collagen Type I / Q000737:chemistry*; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000150:complications / Q000601:surgery*; D004195:Disease Models, Animal; D004427:Ear Diseases / Q000209:etiology / Q000473:pathology; D042783:Endothelial Cells / Q000166:cytology; D008297:Male; D053495:Osteopontin / Q000494:pharmacology*; D011817:Rabbits; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D014182:Transplantation, Autologous; D014456:Ulcer / Q000209:etiology / Q000473:pathology; D014945:Wound Healing / Q000502:physiology*
D024042:Collagen Type I; D053495:Osteopontin; D000496:Alloxan